Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
Surgalign Appoints David Lyle As Chief Financial Officer
Surgalign Holdings, a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. Surgalign acquired UF startup and Sid Martin Biotech alum RTI Surgical in 2020.
Covid-19 Nasal Vaccine Produces Antibodies, Cuts Viral Load
Tests with lab animals show a vaccine given as a nasal spray produces high antibody volumes against SARS-CoV-2 infections and reduces viral loads. Results of tests by biotechnology companies Oragenics Inc., a Sid Martin Biotech alum located in Tampa, and Inspirevax in Laval, Quebec, with National Research Council of Canada, appear on the bioRxiv pre-publication server, and are not yet peer-reviewed.
World Glaucoma Week: A Retina Specialist’s Guide to Recent Innovations in Glaucoma
Ophthalmologists and researchers have made great strides in the management of glaucoma. From implants and robotics to proper administration of eye drops, glaucoma is treated more effectively than ever. This article highlights some of the latest discoveries in glaucoma, including work by UF startup and Sid Martin Biotech company TearClear.
Lacerta Therapeutics Expands Executive Leadership Team
UF startup Lacerta Therapeutics, a preclinical-stage gene therapy company, announces an expansion in the executive leadership team: illustrating Lacerta’s commitment to developing a constellation of gene-based therapies.
RTI Surgical: Plant Director’s Passion and Engagement Inspires Team
A passion to find a position with a company that directly impacts people's lives led Catisha Turner to join UF startup RTI Surgical, after serving in the United States Navy for six years.
Capri EGM Build-to-Suit Program Acquires Life Science Real Estate Asset for Company Manufacturing Antibodies for Department of Defense and mRNA for COVID-19 Vaccine
UF startup Ology Bioservices, a wholly owned subsidiary of Resilience, and the operator of the Lab & Research facility, has recently been awarded contract valued as much as $250 million by the Department of Defense for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
GrowFL Announces Lacerta Therapeutics as an Honoree: 11th Annual Florida Companies to Watch
Lacerta Therapeutics is pleased to be among the top 50 second-stage companies in Florida selected as an 11th Annual GrowFL Florida Companies to Watch honoree, a statewide competition that identifies companies expected to see significant growth over the next several years.
National Resilience Snares Takeda Plasma Development and Manufacturing Deal
Resilience has clinched a deal to chip in on development and manufacturing of “multiple” products in Takeda’s plasma-derived therapies portfolio.
Resilience Subsidiary Ology Bioservices Awarded Contract Worth Up To $250 Million from U.S. Department of Defense for Botulinum Neurotoxin Treatment
The U.S. Department of Defense (DOD) has awarded UF startup Ology Bioservices, Inc. (Ology), a wholly-owned subsidiary of Resilience, a contract valued as much as $250 million for manufacturing development of a monoclonal antibody as a medical countermeasure (MCM) to botulinum neurotoxins (BoNT).
